News headlines about Pain Therapeutics (NASDAQ:PTIE) have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Pain Therapeutics earned a media sentiment score of 0.01 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 46.4737334737812 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
These are some of the news articles that may have effected Accern’s scoring:
- Stock Monitor: Looking at the Levels on Shares of Pain Therapeutics, Inc. (NASDAQ:PTIE) - Sparta Review (spartareview.com)
- Pain Therapeutics Inc (PTIE) Pushes Towards Lower Band - Financial News Review (finnewsreview.com)
- Stock Trading Near the 52-Week Low Pain Therapeutics, Inc. (NASDAQ:PTIE) - Sparta Review (spartareview.com)
- Stock Moving Towards 52-Week Low Pain Therapeutics, Inc. (NASDAQ:PTIE) - Sparta Review (spartareview.com)
Pain Therapeutics (NASDAQ:PTIE) traded down 2.32% during mid-day trading on Friday, hitting $3.37. The stock had a trading volume of 69,365 shares. The firm’s 50-day moving average is $3.93 and its 200 day moving average is $2.00. The company’s market cap is $22.21 million. Pain Therapeutics has a 12 month low of $3.10 and a 12 month high of $21.00.
Pain Therapeutics (NASDAQ:PTIE) last announced its quarterly earnings results on Tuesday, April 25th. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.42). Equities analysts anticipate that Pain Therapeutics will post $1.51 EPS for the current fiscal year.
A number of analysts have recently weighed in on PTIE shares. ValuEngine downgraded Pain Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. Zacks Investment Research downgraded Pain Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, July 14th. Finally, Gabelli downgraded Pain Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, July 17th.
Pain Therapeutics Company Profile
Pain Therapeutics, Inc is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company’s lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company’s other products is FENROCK.
Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
